<html><head></head><body><h1>Sodium Phosphate P 32</h1><p class="drug-subtitle"><b>Dosage Form:</b> intravenous solution<br/></p><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><p class="First">Dear Medical Professional,</p><p>Per your order, we have compounded P32 Sodium Phosphate as a sterile intravenous solution dispensed in a 10 mL plastic vial with a total volume of 4 mL. The characteristics of this preparation are described below.</p><ul>
<li>Description</li>
<li>Indications and Usage</li>
<li>Contraindications</li>
<li>Dosage and Administration</li>
</ul><h2>Sodium Phosphate P 32 Description</h2><p class="First">AnazaoHealthâ€™s compounded P32 sodium phosphate vial is a sterile, non-pyrogenic radiopharmaceutical. The intravenous solution contains 0.25 N sodium acetate buffer, which is made of 0.9% sodium chloride and 0.09% sodium phosphate dibasic, and is compounded to a total volume of 4 mL. The pH of the solution is between 5 and 6.</p><h2>Indications and Usage for Sodium Phosphate P 32</h2><p class="First">P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases</p><h3>Mechanism of Action</h3><p class="First">Radioactive phosphorous concentrates to a very high degree in rapidly proliferating tissues</p><h2>Contraindications</h2><p class="First">P32 sodium phosphate should not be used as part of a sequential treatment with a chemotherapeutic agent. It should not be administered when the leukocyte count is below 5,000/cu mm or a platelet count that is below 150,000/cu mm.</p><p>In chronic myelocytic leukemia, it should not be administered when the leukocyte count is below 20,000/cu mm.</p><p>For the treatment of bone metastases, it is usually not administered when the leukocyte count is below 5,000/ cu mm and platelet count is below 100,000/cu mm</p><h2>Sodium Phosphate P 32 Dosage and Administration</h2><p class="First">For polycythemia vera, intravenous dosages from 1 to 8 mCi are usually given depending upon the stage of disease and the size of the patient. Repeat doses must be adjusted to individual needs. For chronic leukemia, the individual dose is 6 to 15 mCi, usually administered with concomitant hormone manipulation</p><h2>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h2><p class="First"><span class="Bold">Figure 1</span></p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>